These studies coupled to our findings that ereMAPs (i) retain viral-like features (Fig. 6) and (ii) can be recognized by CD8 T cells (Additional file 2: Fig. S7B and C) suggest that ereMAPs may represent particularly attractive targets for the development of cancer vaccines. Here, CD8A is linked to cancer.